1	4	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Discussion	_	_	NN	_	_	_	_	_


1	Within	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	study	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	we	_	_	PRP	_	_	_	_	_
6	used	_	_	VBD	_	_	_	_	_
7	real-time	_	_	JJ	_	_	_	_	_
8	CGM	_	_	NNP	_	_	_	_	_
9	(	_	_	-LRB-	_	_	_	_	_
10	rtCGM	_	_	NNP	_	_	_	_	_
11	)	_	_	-RRB-	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	combination	_	_	NN	_	_	_	_	_
14	with	_	_	IN	_	_	_	_	_
15	a	_	_	DT	_	_	_	_	_
16	serial	_	_	JJ	_	_	_	_	_
17	analysis	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	blood	_	_	NN	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	exhaled	_	_	VBD	_	_	_	_	_
22	breath	_	_	NN	_	_	_	_	_
23	in	_	_	IN	_	_	_	_	_
24	a	_	_	DT	_	_	_	_	_
25	highly	_	_	RB	_	_	_	_	_
26	standardized	_	_	VBN	_	_	_	_	_
27	setting	_	_	NN	_	_	_	_	_
28	in	_	_	IN	_	_	_	_	_
29	pediatric	_	_	JJ	_	_	_	_	_
30	T1DM	_	_	NN	_	_	_	_	_
31	patients	_	_	NNS	_	_	_	_	_
32	and	_	_	CC	_	_	_	_	_
33	healthy	_	_	JJ	_	_	_	_	_
34	controls	_	_	NNS	_	_	_	_	_
35	over	_	_	IN	_	_	_	_	_
36	a	_	_	DT	_	_	_	_	_
37	time	_	_	NN	_	_	_	_	_
38	course	_	_	NN	_	_	_	_	_
39	of	_	_	IN	_	_	_	_	_
40	nine	_	_	CD	_	_	_	_	_
41	hours	_	_	NNS	_	_	_	_	_
42	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	accumulated	_	_	VBD	_	_	_	_	_
3	more	_	_	JJR	_	_	_	_	_
4	than	_	_	IN	_	_	_	_	_
5	4000	_	_	CD	_	_	_	_	_
6	measurements	_	_	NNS	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	breath	_	_	NN	_	_	_	_	_
9	VOCs	_	_	NNS	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	interstitial	_	_	JJ	_	_	_	_	_
12	glucose	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	almost	_	_	RB	_	_	_	_	_
15	1000	_	_	CD	_	_	_	_	_
16	blood	_	_	NN	_	_	_	_	_
17	samples	_	_	NNS	_	_	_	_	_
18	from	_	_	IN	_	_	_	_	_
19	44	_	_	CD	_	_	_	_	_
20	participants	_	_	NNS	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Standardization	_	_	NN	_	_	_	_	_
2	with	_	_	IN	_	_	_	_	_
3	respect	_	_	NN	_	_	_	_	_
4	to	_	_	TO	_	_	_	_	_
5	physical	_	_	JJ	_	_	_	_	_
6	activity	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	interval	_	_	NN	_	_	_	_	_
10	between	_	_	IN	_	_	_	_	_
11	meals	_	_	NNS	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	type	_	_	NN	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	amount	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	nutrients	_	_	NNS	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	restriction	_	_	NN	_	_	_	_	_
23	to	_	_	TO	_	_	_	_	_
24	alveolar	_	_	JJ	_	_	_	_	_
25	breath	_	_	NN	_	_	_	_	_
26	sampling	_	_	NN	_	_	_	_	_
27	allows	_	_	VBZ	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	generation	_	_	NN	_	_	_	_	_
30	of	_	_	IN	_	_	_	_	_
31	highly	_	_	RB	_	_	_	_	_
32	comparable	_	_	JJ	_	_	_	_	_
33	diurnal	_	_	JJ	_	_	_	_	_
34	profiles	_	_	NNS	_	_	_	_	_
35	of	_	_	IN	_	_	_	_	_
36	breath	_	_	NN	_	_	_	_	_
37	and	_	_	CC	_	_	_	_	_
38	blood	_	_	NN	_	_	_	_	_
39	born	_	_	VBN	_	_	_	_	_
40	parameters	_	_	NNS	_	_	_	_	_
41	relative	_	_	JJ	_	_	_	_	_
42	to	_	_	TO	_	_	_	_	_
43	the	_	_	DT	_	_	_	_	_
44	metabolic	_	_	JJ	_	_	_	_	_
45	state	_	_	NN	_	_	_	_	_
46	.	_	_	.	_	_	_	_	_


1	For	_	_	IN	_	_	_	_	_
2	real-time	_	_	JJ	_	_	_	_	_
3	breath	_	_	NN	_	_	_	_	_
4	analysis	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	a	_	_	DT	_	_	_	_	_
7	PTR-ToF-MS	_	_	NN	_	_	_	_	_
8	was	_	_	VBD	_	_	_	_	_
9	used	_	_	VBN	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	we	_	_	PRP	_	_	_	_	_
12	focused	_	_	VBD	_	_	_	_	_
13	on	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	exhalation	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	ethanol	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	acetone	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	isopropanol	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	dimethyl	_	_	NN	_	_	_	_	_
24	sulfide	_	_	NN	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	isoprene	_	_	NN	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	pentanal	_	_	NN	_	_	_	_	_
29	,	_	_	,	_	_	_	_	_
30	and	_	_	CC	_	_	_	_	_
31	limonene	_	_	NN	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	compounds	_	_	NNS	_	_	_	_	_
3	have	_	_	VBP	_	_	_	_	_
4	been	_	_	VBN	_	_	_	_	_
5	linked	_	_	VBN	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	glucose	_	_	NN	_	_	_	_	_
8	metabolism	_	_	NN	_	_	_	_	_
9	and/or	_	_	NN	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	T1DM-related	_	_	JJ	_	_	_	_	_
12	comorbidities	_	_	NNS	_	_	_	_	_
13	including	_	_	VBG	_	_	_	_	_
14	oxidative	_	_	JJ	_	_	_	_	_
15	stress	_	_	NN	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	Thus	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	we	_	_	PRP	_	_	_	_	_
4	investigated	_	_	VBD	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	fade	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	classical	_	_	JJ	_	_	_	_	_
9	markers	_	_	NNS	_	_	_	_	_
10	via	_	_	IN	_	_	_	_	_
11	repetitive	_	_	JJ	_	_	_	_	_
12	blood	_	_	NN	_	_	_	_	_
13	sampling	_	_	NN	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	looked	_	_	VBD	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	parallel	_	_	NN	_	_	_	_	_
18	for	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	VOCs	_	_	NNPS	_	_	_	_	_
21	mentioned	_	_	VBN	_	_	_	_	_
22	above	_	_	RB	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	case	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	T1DM	_	_	NNP	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	acetone	_	_	NN	_	_	_	_	_
8	is	_	_	VBZ	_	_	_	_	_
9	certainly	_	_	RB	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	most	_	_	RBS	_	_	_	_	_
12	prominent	_	_	JJ	_	_	_	_	_
13	VOC	_	_	NN	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	breath	_	_	NN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	has	_	_	VBZ	_	_	_	_	_
18	previously	_	_	RB	_	_	_	_	_
19	been	_	_	VBN	_	_	_	_	_
20	investigated	_	_	VBN	_	_	_	_	_
21	under	_	_	IN	_	_	_	_	_
22	various	_	_	JJ	_	_	_	_	_
23	conditions	_	_	NNS	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	Acetone	_	_	NN	_	_	_	_	_
2	originates	_	_	VBZ	_	_	_	_	_
3	from	_	_	IN	_	_	_	_	_
4	enzymatic	_	_	JJ	_	_	_	_	_
5	or	_	_	CC	_	_	_	_	_
6	non-enzymatic	_	_	JJ	_	_	_	_	_
7	decarboxylation	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	acetoacetate	_	_	NN	_	_	_	_	_
10	via	_	_	IN	_	_	_	_	_
11	Acetyl-CoA	_	_	NNP	_	_	_	_	_
12	which	_	_	WDT	_	_	_	_	_
13	is	_	_	VBZ	_	_	_	_	_
14	derived	_	_	VBN	_	_	_	_	_
15	from	_	_	IN	_	_	_	_	_
16	pyruvate	_	_	NN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	Since	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	latter	_	_	NN	_	_	_	_	_
4	can	_	_	MD	_	_	_	_	_
5	originate	_	_	VB	_	_	_	_	_
6	from	_	_	IN	_	_	_	_	_
7	both	_	_	CC	_	_	_	_	_
8	glycolysis	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	lipolysis	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	it	_	_	PRP	_	_	_	_	_
13	is	_	_	VBZ	_	_	_	_	_
14	impossible	_	_	JJ	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	differentiate	_	_	VB	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	amount	_	_	NN	_	_	_	_	_
19	from	_	_	IN	_	_	_	_	_
20	either	_	_	DT	_	_	_	_	_
21	pathway	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	Regardless	_	_	RB	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	this	_	_	DT	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	we	_	_	PRP	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	others	_	_	NNS	_	_	_	_	_
8	noted	_	_	VBD	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	significantly	_	_	RB	_	_	_	_	_
11	elevated	_	_	VBN	_	_	_	_	_
12	exhalation	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	acetone	_	_	NN	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	T1DM	_	_	NNP	_	_	_	_	_
17	patients	_	_	NNS	_	_	_	_	_
18	compared	_	_	VBN	_	_	_	_	_
19	to	_	_	TO	_	_	_	_	_
20	controls	_	_	NNS	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	as	_	_	RB	_	_	_	_	_
23	well	_	_	RB	_	_	_	_	_
24	as	_	_	IN	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	elevated	_	_	VBN	_	_	_	_	_
27	blood	_	_	NN	_	_	_	_	_
28	levels	_	_	NNS	_	_	_	_	_
29	in	_	_	IN	_	_	_	_	_
30	T1DM	_	_	NNP	_	_	_	_	_
31	patients	_	_	NNS	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	although	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	concentrations	_	_	NNS	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	glucose	_	_	NN	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	acetone	_	_	NN	_	_	_	_	_
10	correlated	_	_	VBN	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	T1DM	_	_	NNP	_	_	_	_	_
13	patients	_	_	NNS	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	time	_	_	NN	_	_	_	_	_
17	and/or	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	interval	_	_	NN	_	_	_	_	_
20	between	_	_	IN	_	_	_	_	_
21	food	_	_	NN	_	_	_	_	_
22	intake	_	_	NN	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	breath	_	_	NN	_	_	_	_	_
26	sampling	_	_	NN	_	_	_	_	_
27	appears	_	_	VBZ	_	_	_	_	_
28	to	_	_	TO	_	_	_	_	_
29	be	_	_	VB	_	_	_	_	_
30	an	_	_	DT	_	_	_	_	_
31	important	_	_	JJ	_	_	_	_	_
32	confounder	_	_	NN	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	morning	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	when	_	_	WRB	_	_	_	_	_
6	ketogenesis	_	_	NN	_	_	_	_	_
7	is	_	_	VBZ	_	_	_	_	_
8	high	_	_	JJ	_	_	_	_	_
9	due	_	_	JJ	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	overnight	_	_	JJ	_	_	_	_	_
12	fasting	_	_	NN	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	correlations	_	_	NNS	_	_	_	_	_
15	were	_	_	VBD	_	_	_	_	_
16	low	_	_	JJ	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	most	_	_	RBS	_	_	_	_	_
19	probably	_	_	RB	_	_	_	_	_
20	due	_	_	JJ	_	_	_	_	_
21	to	_	_	TO	_	_	_	_	_
22	an	_	_	DT	_	_	_	_	_
23	additive	_	_	JJ	_	_	_	_	_
24	effect	_	_	NN	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	lipolysis	_	_	NN	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	glycolysis	_	_	NN	_	_	_	_	_
29	on	_	_	IN	_	_	_	_	_
30	the	_	_	DT	_	_	_	_	_
31	formation	_	_	NN	_	_	_	_	_
32	of	_	_	IN	_	_	_	_	_
33	acetone	_	_	NN	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	Correlation	_	_	NN	_	_	_	_	_
2	improved	_	_	VBD	_	_	_	_	_
3	markedly	_	_	RB	_	_	_	_	_
4	after	_	_	IN	_	_	_	_	_
5	a	_	_	DT	_	_	_	_	_
6	moderate	_	_	JJ	_	_	_	_	_
7	intake	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	carbohydrates	_	_	NNS	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	insulin-related	_	_	JJ	_	_	_	_	_
12	inhibition	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	lipolysis	_	_	NN	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	afternoon	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	correlation	_	_	NN	_	_	_	_	_
6	between	_	_	IN	_	_	_	_	_
7	acetone	_	_	NN	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	blood	_	_	NN	_	_	_	_	_
10	glucose	_	_	NN	_	_	_	_	_
11	remained	_	_	VBD	_	_	_	_	_
12	low	_	_	JJ	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	was	_	_	VBD	_	_	_	_	_
3	most	_	_	RBS	_	_	_	_	_
4	probably	_	_	RB	_	_	_	_	_
5	due	_	_	JJ	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	postprandial	_	_	JJ	_	_	_	_	_
8	hyperglycemia	_	_	NN	_	_	_	_	_
9	.	_	_	.	_	_	_	_	_


1	Thus	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	correlation	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	acetone	_	_	NN	_	_	_	_	_
7	with	_	_	IN	_	_	_	_	_
8	blood	_	_	NN	_	_	_	_	_
9	glucose	_	_	NN	_	_	_	_	_
10	is	_	_	VBZ	_	_	_	_	_
11	difficult	_	_	JJ	_	_	_	_	_
12	even	_	_	RB	_	_	_	_	_
13	under	_	_	IN	_	_	_	_	_
14	healthy	_	_	JJ	_	_	_	_	_
15	conditions	_	_	NNS	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	time-resolved	_	_	JJ	_	_	_	_	_
19	calculation	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	correlation	_	_	NN	_	_	_	_	_
23	coefficients	_	_	NNS	_	_	_	_	_
24	in	_	_	IN	_	_	_	_	_
25	our	_	_	PRP$	_	_	_	_	_
26	study	_	_	NN	_	_	_	_	_
27	strengthen	_	_	VBP	_	_	_	_	_
28	this	_	_	DT	_	_	_	_	_
29	observation	_	_	NN	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	Furthermore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	impact	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	hepatic	_	_	JJ	_	_	_	_	_
7	alcohol	_	_	NN	_	_	_	_	_
8	dehydrogenase	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	i.	_	_	FW	_	_	_	_	_
11	e.	_	_	FW	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	reduction	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	acetone	_	_	NN	_	_	_	_	_
17	to	_	_	TO	_	_	_	_	_
18	isopropanol	_	_	NN	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	has	_	_	VBZ	_	_	_	_	_
21	to	_	_	TO	_	_	_	_	_
22	be	_	_	VB	_	_	_	_	_
23	considered	_	_	VBN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	fact	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	T1DM	_	_	NNP	_	_	_	_	_
5	patients	_	_	NNS	_	_	_	_	_
6	exhaled	_	_	VBD	_	_	_	_	_
7	significantly	_	_	RB	_	_	_	_	_
8	more	_	_	JJR	_	_	_	_	_
9	isopropanol	_	_	NN	_	_	_	_	_
10	than	_	_	IN	_	_	_	_	_
11	their	_	_	PRP$	_	_	_	_	_
12	healthy	_	_	JJ	_	_	_	_	_
13	peers	_	_	NNS	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	both	_	_	DT	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	diurnal	_	_	JJ	_	_	_	_	_
19	profile	_	_	NN	_	_	_	_	_
20	as	_	_	RB	_	_	_	_	_
21	well	_	_	RB	_	_	_	_	_
22	as	_	_	IN	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	time	_	_	NN	_	_	_	_	_
25	resolved	_	_	VBN	_	_	_	_	_
26	correlation	_	_	NN	_	_	_	_	_
27	coefficients	_	_	NNS	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	closely	_	_	RB	_	_	_	_	_
30	resembled	_	_	VBD	_	_	_	_	_
31	that	_	_	DT	_	_	_	_	_
32	of	_	_	IN	_	_	_	_	_
33	acetone	_	_	NN	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	Thus	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	activation	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	this	_	_	DT	_	_	_	_	_
6	pathway	_	_	NN	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	T1DM	_	_	NN	_	_	_	_	_
9	patients	_	_	NNS	_	_	_	_	_
10	may	_	_	MD	_	_	_	_	_
11	attribute	_	_	VB	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	acetone	_	_	NN	_	_	_	_	_
14	elimination	_	_	NN	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	indicate	_	_	VB	_	_	_	_	_
17	metabolic	_	_	JJ	_	_	_	_	_
18	adaptation	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	shape	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	normalized	_	_	VBN	_	_	_	_	_
6	diurnal	_	_	JJ	_	_	_	_	_
7	profiles	_	_	NNS	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	glucose	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	insulin	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	glucagon	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	lipids	_	_	NNS	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	leptin	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	slepR	_	_	NN	_	_	_	_	_
21	are	_	_	VBP	_	_	_	_	_
22	fairly	_	_	RB	_	_	_	_	_
23	comparable	_	_	JJ	_	_	_	_	_
24	in	_	_	IN	_	_	_	_	_
25	T1DM	_	_	NN	_	_	_	_	_
26	patients	_	_	NNS	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	healthy	_	_	JJ	_	_	_	_	_
29	controls	_	_	NNS	_	_	_	_	_
30	,	_	_	,	_	_	_	_	_
31	but	_	_	CC	_	_	_	_	_
32	differ	_	_	VBP	_	_	_	_	_
33	with	_	_	IN	_	_	_	_	_
34	respect	_	_	NN	_	_	_	_	_
35	to	_	_	TO	_	_	_	_	_
36	slope	_	_	NN	_	_	_	_	_
37	and	_	_	CC	_	_	_	_	_
38	inter-individual	_	_	JJ	_	_	_	_	_
39	variability	_	_	NN	_	_	_	_	_
40	,	_	_	,	_	_	_	_	_
41	i.	_	_	FW	_	_	_	_	_
42	e.	_	_	FW	_	_	_	_	_
43	,	_	_	,	_	_	_	_	_
44	changes	_	_	NNS	_	_	_	_	_
45	over	_	_	IN	_	_	_	_	_
46	time	_	_	NN	_	_	_	_	_
47	are	_	_	VBP	_	_	_	_	_
48	faster	_	_	JJR	_	_	_	_	_
49	in	_	_	IN	_	_	_	_	_
50	controls	_	_	NNS	_	_	_	_	_
51	while	_	_	IN	_	_	_	_	_
52	inter-individual	_	_	JJ	_	_	_	_	_
53	variability	_	_	NN	_	_	_	_	_
54	is	_	_	VBZ	_	_	_	_	_
55	much	_	_	RB	_	_	_	_	_
56	greater	_	_	JJR	_	_	_	_	_
57	in	_	_	IN	_	_	_	_	_
58	T1DM	_	_	NNP	_	_	_	_	_
59	patients	_	_	NNS	_	_	_	_	_
60	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	might	_	_	MD	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	at	_	_	IN	_	_	_	_	_
5	least	_	_	JJS	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	part	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	be	_	_	VB	_	_	_	_	_
10	due	_	_	JJ	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	limited	_	_	JJ	_	_	_	_	_
14	abilities	_	_	NNS	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	pharmaceutical	_	_	JJ	_	_	_	_	_
17	insulin	_	_	NN	_	_	_	_	_
18	preparations	_	_	NNS	_	_	_	_	_
19	to	_	_	TO	_	_	_	_	_
20	mimic	_	_	VB	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	physiological	_	_	JJ	_	_	_	_	_
23	interplay	_	_	NN	_	_	_	_	_
24	between	_	_	IN	_	_	_	_	_
25	insulin-induced	_	_	JJ	_	_	_	_	_
26	cellular	_	_	JJ	_	_	_	_	_
27	uptake	_	_	NN	_	_	_	_	_
28	of	_	_	IN	_	_	_	_	_
29	glucose	_	_	NN	_	_	_	_	_
30	and	_	_	CC	_	_	_	_	_
31	glucagon	_	_	NN	_	_	_	_	_
32	secretion	_	_	NN	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	Under	_	_	IN	_	_	_	_	_
2	physiological	_	_	JJ	_	_	_	_	_
3	conditions	_	_	NNS	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	insulin	_	_	NN	_	_	_	_	_
6	is	_	_	VBZ	_	_	_	_	_
7	secreted	_	_	VBN	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	response	_	_	NN	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	increasing	_	_	VBG	_	_	_	_	_
12	blood	_	_	NN	_	_	_	_	_
13	glucose	_	_	NN	_	_	_	_	_
14	levels	_	_	NNS	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	by	_	_	IN	_	_	_	_	_
17	inducing	_	_	VBG	_	_	_	_	_
18	cellular	_	_	JJ	_	_	_	_	_
19	glucose	_	_	NN	_	_	_	_	_
20	uptake	_	_	NN	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	inhibition	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	pancreatic	_	_	JJ	_	_	_	_	_
25	glucagon	_	_	NN	_	_	_	_	_
26	secretion	_	_	NN	_	_	_	_	_
27	at	_	_	IN	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	same	_	_	JJ	_	_	_	_	_
30	time	_	_	NN	_	_	_	_	_
31	it	_	_	PRP	_	_	_	_	_
32	contributes	_	_	VBZ	_	_	_	_	_
33	to	_	_	TO	_	_	_	_	_
34	maintenance	_	_	NN	_	_	_	_	_
35	of	_	_	IN	_	_	_	_	_
36	glucose	_	_	NN	_	_	_	_	_
37	homeostasis	_	_	NN	_	_	_	_	_
38	.	_	_	.	_	_	_	_	_


1	Thus	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	in	_	_	IN	_	_	_	_	_
4	healthy	_	_	JJ	_	_	_	_	_
5	individuals	_	_	NNS	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	glucagon	_	_	NN	_	_	_	_	_
8	concentration	_	_	NN	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	blood	_	_	NN	_	_	_	_	_
11	remains	_	_	VBZ	_	_	_	_	_
12	constant	_	_	JJ	_	_	_	_	_
13	as	_	_	RB	_	_	_	_	_
14	long	_	_	RB	_	_	_	_	_
15	as	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	blood	_	_	NN	_	_	_	_	_
18	glucose	_	_	NN	_	_	_	_	_
19	concentration	_	_	NN	_	_	_	_	_
20	stays	_	_	VBZ	_	_	_	_	_
21	within	_	_	IN	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	normal	_	_	JJ	_	_	_	_	_
24	range	_	_	NN	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	insulin	_	_	NN	_	_	_	_	_
27	concentrations	_	_	NNS	_	_	_	_	_
28	peak	_	_	VBP	_	_	_	_	_
29	after	_	_	IN	_	_	_	_	_
30	meals	_	_	NNS	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	contrast	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	T1DM	_	_	NN	_	_	_	_	_
6	patients	_	_	NNS	_	_	_	_	_
7	glucagon	_	_	NN	_	_	_	_	_
8	concentrations	_	_	NNS	_	_	_	_	_
9	remain	_	_	VBP	_	_	_	_	_
10	partially	_	_	RB	_	_	_	_	_
11	elevated	_	_	VBN	_	_	_	_	_
12	even	_	_	RB	_	_	_	_	_
13	after	_	_	IN	_	_	_	_	_
14	meals	_	_	NNS	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	most	_	_	RBS	_	_	_	_	_
17	likely	_	_	RB	_	_	_	_	_
18	aggravate	_	_	VBP	_	_	_	_	_
19	postprandial	_	_	JJ	_	_	_	_	_
20	hyperglycemia	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	latter	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	especially	_	_	RB	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	concert	_	_	NN	_	_	_	_	_
7	with	_	_	IN	_	_	_	_	_
8	dyslipidemia	_	_	NN	_	_	_	_	_
9	is	_	_	VBZ	_	_	_	_	_
10	considered	_	_	VBN	_	_	_	_	_
11	as	_	_	IN	_	_	_	_	_
12	a	_	_	DT	_	_	_	_	_
13	relevant	_	_	JJ	_	_	_	_	_
14	contributor	_	_	NN	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	overall	_	_	JJ	_	_	_	_	_
18	increased	_	_	VBN	_	_	_	_	_
19	risk	_	_	NN	_	_	_	_	_
20	for	_	_	IN	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	development	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	cardiovascular	_	_	JJ	_	_	_	_	_
25	disease	_	_	NN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	On	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	one	_	_	CD	_	_	_	_	_
4	hand	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	poor	_	_	JJ	_	_	_	_	_
7	glycemic	_	_	JJ	_	_	_	_	_
8	control	_	_	NN	_	_	_	_	_
9	is	_	_	VBZ	_	_	_	_	_
10	likely	_	_	JJ	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	result	_	_	VB	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	elevated	_	_	VBN	_	_	_	_	_
15	cholesterol	_	_	NN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	triglyceride	_	_	NN	_	_	_	_	_
18	levels	_	_	NNS	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	on	_	_	IN	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	other	_	_	JJ	_	_	_	_	_
23	hand	_	_	NN	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	peripheral	_	_	JJ	_	_	_	_	_
26	hyperinsulinemia	_	_	NN	_	_	_	_	_
27	secondary	_	_	JJ	_	_	_	_	_
28	to	_	_	TO	_	_	_	_	_
29	subcutaneous	_	_	JJ	_	_	_	_	_
30	insulin	_	_	NN	_	_	_	_	_
31	administration	_	_	NN	_	_	_	_	_
32	contribute	_	_	VB	_	_	_	_	_
33	to	_	_	TO	_	_	_	_	_
34	qualitative	_	_	JJ	_	_	_	_	_
35	abnormalities	_	_	NNS	_	_	_	_	_
36	of	_	_	IN	_	_	_	_	_
37	lipid	_	_	NN	_	_	_	_	_
38	metabolism	_	_	NN	_	_	_	_	_
39	as	_	_	RB	_	_	_	_	_
40	well	_	_	RB	_	_	_	_	_
41	and	_	_	CC	_	_	_	_	_
42	this	_	_	DT	_	_	_	_	_
43	has	_	_	VBZ	_	_	_	_	_
44	recently	_	_	RB	_	_	_	_	_
45	been	_	_	VBN	_	_	_	_	_
46	shown	_	_	VBN	_	_	_	_	_
47	in	_	_	IN	_	_	_	_	_
48	young	_	_	JJ	_	_	_	_	_
49	T1DM	_	_	NN	_	_	_	_	_
50	patients	_	_	NNS	_	_	_	_	_
51	.	_	_	.	_	_	_	_	_


1	Albeit	_	_	IN	_	_	_	_	_
2	no	_	_	DT	_	_	_	_	_
3	clear	_	_	JJ	_	_	_	_	_
4	correlation	_	_	NN	_	_	_	_	_
5	between	_	_	IN	_	_	_	_	_
6	breath	_	_	NN	_	_	_	_	_
7	ethanol	_	_	NN	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	serum	_	_	NN	_	_	_	_	_
10	triglycerides	_	_	NNS	_	_	_	_	_
11	exists	_	_	VBZ	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	concentration	_	_	NN	_	_	_	_	_
15	profiles	_	_	NNS	_	_	_	_	_
16	were	_	_	VBD	_	_	_	_	_
17	quite	_	_	RB	_	_	_	_	_
18	similar	_	_	JJ	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	especially	_	_	RB	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	second	_	_	JJ	_	_	_	_	_
24	half	_	_	NN	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	the	_	_	DT	_	_	_	_	_
27	examination	_	_	NN	_	_	_	_	_
28	period	_	_	NN	_	_	_	_	_
29	,	_	_	,	_	_	_	_	_
30	i.	_	_	FW	_	_	_	_	_
31	e.	_	_	FW	_	_	_	_	_
32	,	_	_	,	_	_	_	_	_
33	after	_	_	IN	_	_	_	_	_
34	challenge	_	_	NN	_	_	_	_	_
35	with	_	_	IN	_	_	_	_	_
36	carbohydrates	_	_	NNS	_	_	_	_	_
37	(	_	_	-LRB-	_	_	_	_	_
38	pasta	_	_	NN	_	_	_	_	_
39	)	_	_	-RRB-	_	_	_	_	_
40	at	_	_	IN	_	_	_	_	_
41	lunch	_	_	NN	_	_	_	_	_
42	.	_	_	.	_	_	_	_	_


1	Endogenous	_	_	JJ	_	_	_	_	_
2	ethanol	_	_	NN	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	supposed	_	_	VBN	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	originate	_	_	VB	_	_	_	_	_
7	from	_	_	IN	_	_	_	_	_
8	intestinal	_	_	JJ	_	_	_	_	_
9	bacterial	_	_	JJ	_	_	_	_	_
10	activity	_	_	NN	_	_	_	_	_
11	via	_	_	IN	_	_	_	_	_
12	fermentation	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	carbohydrates	_	_	NNS	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	i.	_	_	FW	_	_	_	_	_
17	e.	_	_	FW	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	breath	_	_	NN	_	_	_	_	_
20	ethanol	_	_	NN	_	_	_	_	_
21	increase	_	_	NN	_	_	_	_	_
22	is	_	_	VBZ	_	_	_	_	_
23	due	_	_	JJ	_	_	_	_	_
24	to	_	_	TO	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	intake	_	_	NN	_	_	_	_	_
27	with	_	_	IN	_	_	_	_	_
28	subsequent	_	_	JJ	_	_	_	_	_
29	digestion	_	_	NN	_	_	_	_	_
30	of	_	_	IN	_	_	_	_	_
31	carbohydrates	_	_	NNS	_	_	_	_	_
32	and	_	_	CC	_	_	_	_	_
33	the	_	_	DT	_	_	_	_	_
34	intestinal	_	_	JJ	_	_	_	_	_
35	microbiota	_	_	NN	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_


1	While	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	carbohydrate	_	_	NN	_	_	_	_	_
4	intake	_	_	NN	_	_	_	_	_
5	at	_	_	IN	_	_	_	_	_
6	lunch	_	_	NN	_	_	_	_	_
7	was	_	_	VBD	_	_	_	_	_
8	quite	_	_	RB	_	_	_	_	_
9	similar	_	_	JJ	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	both	_	_	DT	_	_	_	_	_
12	groups	_	_	NNS	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	postprandial	_	_	JJ	_	_	_	_	_
15	hyperglycemia	_	_	NN	_	_	_	_	_
16	was	_	_	VBD	_	_	_	_	_
17	not	_	_	RB	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	even	_	_	RB	_	_	_	_	_
20	subtle	_	_	JJ	_	_	_	_	_
21	differences	_	_	NNS	_	_	_	_	_
22	with	_	_	IN	_	_	_	_	_
23	respect	_	_	NN	_	_	_	_	_
24	to	_	_	TO	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	intestinal	_	_	JJ	_	_	_	_	_
27	microbiota	_	_	NN	_	_	_	_	_
28	between	_	_	IN	_	_	_	_	_
29	T1DM	_	_	NN	_	_	_	_	_
30	patients	_	_	NNS	_	_	_	_	_
31	and	_	_	CC	_	_	_	_	_
32	controls	_	_	NNS	_	_	_	_	_
33	have	_	_	VBP	_	_	_	_	_
34	to	_	_	TO	_	_	_	_	_
35	be	_	_	VB	_	_	_	_	_
36	considered	_	_	VBN	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_


1	Altogether	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	this	_	_	DT	_	_	_	_	_
4	may	_	_	MD	_	_	_	_	_
5	have	_	_	VB	_	_	_	_	_
6	caused	_	_	VBN	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	slightly	_	_	RB	_	_	_	_	_
9	more	_	_	RBR	_	_	_	_	_
10	pronounced	_	_	VBN	_	_	_	_	_
11	increase	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	postprandial	_	_	JJ	_	_	_	_	_
14	ethanol	_	_	NN	_	_	_	_	_
15	with	_	_	IN	_	_	_	_	_
16	higher	_	_	JJR	_	_	_	_	_
17	peak	_	_	NN	_	_	_	_	_
18	ethanol	_	_	NN	_	_	_	_	_
19	concentrations	_	_	NNS	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	T1DM	_	_	NNP	_	_	_	_	_
22	patients	_	_	NNS	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Elevated	_	_	VBN	_	_	_	_	_
2	endogenous	_	_	JJ	_	_	_	_	_
3	ethanol	_	_	NN	_	_	_	_	_
4	was	_	_	VBD	_	_	_	_	_
5	also	_	_	RB	_	_	_	_	_
6	already	_	_	RB	_	_	_	_	_
7	previously	_	_	RB	_	_	_	_	_
8	detected	_	_	VBN	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	diabetic	_	_	JJ	_	_	_	_	_
11	patients	_	_	NNS	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_

